Breast cancer subtypes and survival in Chinese women with operable primary breast cancer
Breast cancer subtypes and survival in Chinese women with operable primary breast cancer
复制标题
中国可手术原发性乳腺癌女性的乳腺癌亚型和生存率
DOI：
10.1007/s11670-011-0134-z
复制
发表时间：
2011-06-01
影响因子：
5.1
通讯作者：
Xie, Yun-tao
中科院分区：
文献类型：
--
作者：
Li, Zhao-sheng;Yao, Lu;Xie, Yun-tao
探讨不同乳腺癌亚型与中国可手术原发性乳腺癌患者生存率的关系。本研究共分析1538例中国可手术原发性乳腺癌患者，中位随访时间为77个月。这些患者的雌激素受体（ER）、孕激素受体（PR）和HER2状态均可获得。与整个队列中的其他亚型相比，Luminal A （ER+和/或PR+， HER2-）具有良好的无病生存期（DFS）和总生存期（OS）。以腔内A为参照，在淋巴结阳性患者中，HER2+ （ER-、PR-、HER2+）的DFS最差（风险比，HR=1.80, 95% CI 1.11 ~ 2.91， P=0.017），而腔内B （ER+和/或PR+， HER2+）的OS最差（HR=2.27, 95% CI 1.50 ~ 3.45, P < 0.001）；在淋巴结阴性患者中，三阴性（ER-、PR-、HER2-）的DFS最差（HR=2.21, 95% CI 1.43 ~ 3.41, P < 0.001），而HER2+与腔内B、腔内A的DFS差异无统计学意义。与管腔A相比，管腔B和HER2+在淋巴结阳性疾病患者中生存率最差，但在淋巴结阴性疾病患者中并非如此；三阴性亚型在淋巴结阳性和淋巴结阴性患者中生存率都较差。
To investigate the associations between the different breast cancer subtypes and survival in Chinese women with operable primary breast cancer.A total of 1538 Chinese women with operable primary breast cancer were analyzed in this study, the median follow-up was 77 months. Estrogen receptor (ER), progesterone receptor (PR), and HER2 status were available for these patients.Luminal A (ER+ and/or PR+, HER2-) had a favorable disease-free survival (DFS) and overall survival (OS) compared with other subtypes in the entire cohort. Using the luminal A as a reference, among the patients with lymph node positive disease, HER2+ (ER-, PR-, HER2+) had the worst DFS (hazard ratio, HR=1.80, 95% CI 1.11 to 2.91, P=0.017) and luminal B (ER+ and/or PR+, HER2+) had the worst OS (HR=2.27, 95% CI 1.50 to 3.45, P < 0.001); among the patients with lymph node negative disease, triple-negative (ER-, PR-, HER2-) had the worst DFS (HR=2.21, 95% CI 1.43 to 3.41, P < 0.001), whereas no significant difference in DFS between HER2+ and luminal B or luminal A was observed.As compared with luminal A, luminal B and HER2+ have the worst survival in patients with lymph node positive disease, but this is not the case in patients with lymph node negative disease; triple-negative subtype has a worse survival in both lymph node positive and lymph node negative patients.